Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma Mauricette Michallet, Thierry.

Slides:

Advertisements

Similar presentations

© 2014 sanofi-aventis U.S. LLC, A SANOFI COMPANY All rights reserved US.PLE Brief Overview of Hematopoietic Cell Transplantation (HCT) Use.

Advertisements

Oxidative stress and hypoxia in normal and leukemic stem cells Ugo Testa, Catherine Labbaye, Germana Castelli, Elvira Pelosi Experimental Hematology Volume.

Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation.

From: High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study Ann Intern Med. 2004;140(2):85-93.

Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies: a 10-year.

Autologous Peripheral Blood Stem Cell Rescue. Multiple Myeloma.

Lenograstim Chemical Formula : C840-H1330-N222-O242-S8

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors.

Peripheral Blood Stem Cell Rescue. Multiple Myeloma.

Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation.

Volume 18, Issue 1, Pages (January 2016)

Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase.

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic.

George E. Georges, Vladimir Lesnikov, Szczepan W

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

Figure 1 Outline of the AHSCT procedure

Temporal Changes in Plerixafor Administration and Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial in Multiple Myeloma

Peripheral Blood Stem Cell Rescue. Multiple Myeloma.

Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and β-thalassemia Robert Iannone, James F Casella, Ephraim.

Adoptive Cellular Therapy using Cells Enriched for NKG2D+CD3+CD8+T Cells after Autologous Transplantation for Myeloma Kenneth R. Meehan, Laleh Talebian,

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G- CSF and Plerixafor Compared to G-CSF and Cyclophosphamide Paul Shaughnessy,

Effect of Obesity on Outcomes after Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma Dan T. Vogl, Tao Wang, Waleska S. Pérez,

Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation.

Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders Orly R. Klein, Allen.

A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide,

Francis Hérodin, Michel Drouet Experimental Hematology

The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell.

Impact of Mobilization and Remobilization Strategies on Achieving Sufficient Stem Cell Yields for Autologous Transplantation Iskra Pusic, Shi Yuan Jiang,

The Use of Experimental Murine Models to Assess Novel Agents of Hematopoietic Stem and Progenitor Cell Mobilization Kirsten E. Herbert, Jean-Pierre Lévesque,

Does PBSC Product Platelet Content Affect Outcomes of Autologous Peripheral Blood Stem Cell Transplant? Raisa Pinto, Najla El Jurdi, Fahrettin Covut,

Mobilization of Hematopoietic Progenitors from Normal Donors Using the Combination of Granulocyte-Macrophage Colony-Stimulating Factor and Granulocyte.

An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for.

Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony–Stimulating Factor in Lymphoma Patients Undergoing Autologous.

Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing.

Biology of Blood and Marrow Transplantation

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in.

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma

Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic.

Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma:

Long-term marrow reconstitutive ability of autologous grafts in lymphoma patients using peripheral blood mobilized with granulocyte colony-stimulating.

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients Irene Schmid, Daniel Stachel,

Volume 141, Issue 1, Pages (July 2011)

Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.

Similar Outcomes of Cryopreserved Allogeneic Peripheral Stem Cell Transplants (PBSCT) Compared to Fresh Allografts Dong Hwan Kim, Nazir Jamal, Ronnie.

Incidence of Adrenal Insufficiency in Patients with Multiple Myeloma during High Dose Chemotherapy and Autologous Stem Cell Transplant Ahmad Hatem Mattour,

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation Mohammed M. Elayan, Justin G.

Salvage Allogeneic Hematopoietic Cell Transplantation with Fludarabine and Low-Dose Total Body Irradiation after Rejection of First Allografts Boglarka.

Non-CD34+ Cells, Especially CD8+ Cytotoxic T Cells and CD56+ Natural Killer Cells, Rather Than CD34 Cells, Predict Early Engraftment and Better Transplantation.

Influence of Body Weight on Melphalan Dosing in Autologous Stem Cell Transplantation Kendall Shultes, Christopher Arp, Keith Stockerl-Goldstein, Kathryn.

Angiogenesis and arteriogenesis in limb ischemia

Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation J.R. Molina,

Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic.

Pharmacological Immunosuppression Reduces But Does Not Eliminate the Need for Total-Body Irradiation in Nonmyeloablative Conditioning Regimens for Hematopoietic.

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

Bridge to transplant following Bv+Bs regimen.

Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350 cGy) and Fludarabine Conditioning Junya Kanda, David.

Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation Charles Linker, Paolo Anderlini,

Addition of Plerixafor to Mobilization Regimens in Autologous Peripheral Blood Stem Cell Transplants Does Not Affect the Correlation of Preharvest Hematopoietic.

Long-term persistent lymphopenia in hematopoietic stem cell donors after donation for donor lymphocyte infusion Franck E. Nicolini, Eric Wattel, Anne-Sophie.

A Phase I Study in Adults of Clofarabine Combined with High-Dose Melphalan as Reduced-Intensity Conditioning for Allogeneic Transplantation Mark H. Kirschbaum,

Older Age But Not Donor Health Impairs Allogeneic Granulocyte Colony-Stimulating Factor (G-CSF) Peripheral Blood Stem Cell Mobilization Elie Richa, Mona.

Cryopreserved CD34+ Cell Dose, but Not Total Nucleated Cell Dose, Influences Hematopoietic Recovery and Extensive Chronic Graft-versus-Host Disease after.

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Fig. 3. Generation of induced microglia like cells from peripheral blood mononuclear cells (A) and defected microglial phagocytosis in rapidly progressive.

Autologous Stem Cell Transplantation for POEMS Syndrome

Haploidentical stem cell transplantation with purified CD34+ cells after a chemotherapy- alone conditioning regimen J.F Lacerda, C Martins, J.A Carmo,

Presentation transcript:

Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma Mauricette Michallet, Thierry Philip, Irène Philip, Hubert Godinot, Catherine Sebban, Gilles Salles, Anne Thiebaut, Pierre Biron, Francis Lopez, Philippe Mazars, Nora Roubi, Tom Leemhuis, Elie Hanania, Christopher Reading, Gilbert Fine, Kerry Atkinson, Chris Juttner, Bertrand Coiffier, Denis Fière, Eric Archimbaud Experimental Hematology Volume 28, Issue 7, Pages 858-870 (July 2000) DOI: 10.1016/S0301-472X(00)00169-7

Figure 1 Schema of study design. Patients were mobilized with granulocyte-macrophage colony-stimulating factor (GM-CSF) and cyclophosphamide. Peripheral blood mononuclear cells (PBMC) were collected and CD34+Thy1+cells selected using a two-step process. For safety concerns with this new source of cells, the first cohort of patient recieved melphalan alone as conditioning regimen followed by CD34+Thy1+ infusion. Subsequent patient cohorts received melphalan + total body irradiation (TBI) and decreasing numbers of CD34+Thy1+ cells. Progression from cohort 1 to 4 was based on the demonstration of sustained engraftment and adequate safety in the current cohort. The fifth cohort was added after considering poor engraftment results with the low CD34+Thy1+ cell dose cohorts. All patients received G-CSF after transplant and were followed-up 1 year after transplant Experimental Hematology 2000 28, 858-870DOI: (10.1016/S0301-472X(00)00169-7)

Figure 2 Neutrophil and platelet engraftment after transplant (median values) for melphalan + total body irradiation (TBI) regimen. Gray areas represent normal laboratory ranges Experimental Hematology 2000 28, 858-870DOI: (10.1016/S0301-472X(00)00169-7)

Figure 3 T-cell subset kinetics after transplant (median values). Gray areas represent normal laboratory ranges Experimental Hematology 2000 28, 858-870DOI: (10.1016/S0301-472X(00)00169-7)